These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16034306)

  • 1. An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients.
    Alexis JB; Martinez AE; Lutzky J
    Melanoma Res; 2005 Aug; 15(4):283-5. PubMed ID: 16034306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
    Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
    Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
    Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
    Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major response to imatinib mesylate in KIT-mutated melanoma.
    Hodi FS; Friedlander P; Corless CL; Heinrich MC; Mac Rae S; Kruse A; Jagannathan J; Van den Abbeele AD; Velazquez EF; Demetri GD; Fisher DE
    J Clin Oncol; 2008 Apr; 26(12):2046-51. PubMed ID: 18421059
    [No Abstract]   [Full Text] [Related]  

  • 6. Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
    Fiorentini G; Rossi S; Lanzanova G; Biancalani M; Palomba A; Bernardeschi P; Dentico P; De Giorgi U
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):17-20. PubMed ID: 16767900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.
    Cristofanilli M; Morandi P; Krishnamurthy S; Reuben JM; Lee BN; Francis D; Booser DJ; Green MC; Arun BK; Pusztai L; Lopez A; Islam R; Valero V; Hortobagyi GN
    Ann Oncol; 2008 Oct; 19(10):1713-9. PubMed ID: 18515258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of clinical efficacy of imatinib in metastatic melanoma.
    Ugurel S; Hildenbrand R; Zimpfer A; La Rosée P; Paschka P; Sucker A; Keikavoussi P; Becker JC; Rittgen W; Hochhaus A; Schadendorf D
    Br J Cancer; 2005 Apr; 92(8):1398-405. PubMed ID: 15846297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT as a therapeutic target in metastatic melanoma.
    Carvajal RD; Antonescu CR; Wolchok JD; Chapman PB; Roman RA; Teitcher J; Panageas KS; Busam KJ; Chmielowski B; Lutzky J; Pavlick AC; Fusco A; Cane L; Takebe N; Vemula S; Bouvier N; Bastian BC; Schwartz GK
    JAMA; 2011 Jun; 305(22):2327-34. PubMed ID: 21642685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential use of imatinib mesylate in ocular melanoma and liposarcoma expressing immunohistochemical c-KIT (CD117).
    Fiorentini G; Rossi S; Lanzanova G; Bernardeschi P; Dentico P; De Giorgi U
    Ann Oncol; 2003 May; 14(5):805. PubMed ID: 12702540
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
    Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
    J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
    Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
    J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.
    Allegra M; Giacchero D; Segalen C; Dumaz N; Butori C; Hofman V; Hofman P; Lacour JP; Bertolotto C; Bahadoran P; Ballotti R
    J Invest Dermatol; 2014 May; 134(5):1473-1476. PubMed ID: 24317392
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
    Handolias D; Hamilton AL; Salemi R; Tan A; Moodie K; Kerr L; Dobrovic A; McArthur GA
    Br J Cancer; 2010 Apr; 102(8):1219-23. PubMed ID: 20372153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
    Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O'Day S; Kim K; Hodi FS; Van den Abbeele AD
    Cancer Imaging; 2014 Nov; 14(1):30. PubMed ID: 25609545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecularly targeted therapies for melanoma.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.
    Giaccone G; Rajan A; Ruijter R; Smit E; van Groeningen C; Hogendoorn PC
    J Thorac Oncol; 2009 Oct; 4(10):1270-3. PubMed ID: 20197733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.